Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$18.31 -2.9%	$15.87	$9.57 ▼ $30.41	$2.60B	0.93	1.56 million shs	1.45 million shs
EBS Emergent Biosolutions	$7.34 +0.1%	$6.40	$4.02 ▼ $15.10	$397.86M	2.09	1.70 million shs	1.05 million shs
FGEN FibroGen	$7.15 -2.7%	$6.97	$4.50 ▼ $38.25	$28.90M	0.74	76,113 shs	59,782 shs
PTCT PTC Therapeutics	$48.55 -2.0%	$48.09	$29.02 ▼ $58.38	$3.85B	0.5	872,801 shs	760,569 shs
ZLAB Zai Lab	$32.73 -4.0%	$34.09	$16.01 ▼ $44.34	$3.64B	0.99	917,123 shs	1.03 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-2.92%	+9.12%	+9.38%	+55.30%	-31.73%
EBS Emergent Biosolutions	+0.14%	+5.01%	+9.88%	+67.92%	-20.99%
FGEN FibroGen	-2.72%	+25.66%	-7.44%	+3.17%	-68.34%
PTCT PTC Therapeutics	-1.96%	-0.45%	-4.47%	+12.96%	+52.82%
ZLAB Zai Lab	-3.96%	-10.16%	-20.94%	+10.80%	+91.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5902 of 5 stars	3.4	2.0	3.4	2.1	1.7	0.0
EBS Emergent Biosolutions	4.265 of 5 stars	3.5	1.0	4.6	2.1	2.5	1.3
FGEN FibroGen	4.7285 of 5 stars	3.3	4.0	4.7	3.8	3.3	0.6
PTCT PTC Therapeutics	4.3456 of 5 stars	4.3	1.0	4.4	2.0	0.8	1.3
ZLAB Zai Lab	3.0695 of 5 stars	3.4	5.0	0.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	138.75% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	95.28% Upside
FGEN FibroGen	2.50	Moderate Buy	$250.00	3,396.50% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	33.88% Upside
ZLAB Zai Lab	2.80	Moderate Buy	$54.28	65.83% Upside

Current Analyst Ratings Breakdown

Latest ARWR, ZLAB, PTCT, FGEN, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	ZLAB Zai Lab	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$73.00 ➝ $75.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00
5/8/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/7/2025	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$57.00 ➝ $58.00
5/7/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$70.00 ➝ $66.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	712.28	N/A	N/A	$1.54 per share	11.89
EBS Emergent Biosolutions	$1.04B	0.38	$1.92 per share	3.82	$8.91 per share	0.82
FGEN FibroGen	$7.00M	4.13	N/A	N/A	($50.89) per share	-0.14
PTCT PTC Therapeutics	$1.77B	2.17	N/A	N/A	($14.24) per share	-3.41
ZLAB Zai Lab	$418.33M	8.69	N/A	N/A	$7.68 per share	4.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	22.18	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.55	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.46	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/7/2025 (Estimated)

Latest ARWR, ZLAB, PTCT, FGEN, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	EBS Emergent Biosolutions	$0.21	N/A	N/A	N/A	$148.55 million	N/A
8/5/2025	Q2 2025	FGEN FibroGen	-$0.09	N/A	N/A	N/A	$2.88 million	N/A
8/5/2025	Q2 2025	ZLAB Zai Lab	-$0.42	N/A	N/A	N/A	$125.66 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
EBS Emergent Biosolutions	1.20	6.32	3.51
FGEN FibroGen	N/A	2.02	1.98
PTCT PTC Therapeutics	N/A	3.89	3.85
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
EBS Emergent Biosolutions	78.40%
FGEN FibroGen	72.71%
PTCT PTC Therapeutics	N/A
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
EBS Emergent Biosolutions	1.20%
FGEN FibroGen	3.07%
PTCT PTC Therapeutics	5.50%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
ZLAB Zai Lab	1,869	111.08 million	105.57 million	Optionable

ARWR, ZLAB, PTCT, FGEN, and EBS Headlines

Recent News About These Companies

Alps Advisors Inc. Sells 12,097 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 12 at 5:37 AM | marketbeat.com

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

July 10 at 8:01 AM | businesswire.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?

July 8, 2025 | marketbeat.com

67,159 Shares in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Bought by Penserra Capital Management LLC

July 8, 2025 | marketbeat.com

Principal Financial Group Inc. Purchases 1,121,856 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 5, 2025 | marketbeat.com

Brokerages Set Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Target Price at $54.28

July 5, 2025 | americanbankingnews.com

Zai Lab FY2025 EPS Estimate Decreased by Cantor Fitzgerald

July 4, 2025 | americanbankingnews.com

Ying Du Sells 7,072 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

July 3, 2025 | marketbeat.com

Cantor Fitzgerald Lowers Earnings Estimates for Zai Lab

July 3, 2025 | marketbeat.com

FY2026 EPS Estimates for Zai Lab Raised by Leerink Partnrs

July 3, 2025 | americanbankingnews.com

Leerink Partnrs Analysts Lift Earnings Estimates for Zai Lab

July 2, 2025 | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 6,918 Shares of Stock

July 2, 2025 | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $245,727.36 in Stock

July 1, 2025 | marketbeat.com

Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint

July 1, 2025 | finance.yahoo.com

Amgen, Zai Lab succeed in gastric cancer study

June 30, 2025 | msn.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of "Moderate Buy" by Analysts

June 30, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Price Target Raised to $75.00 at Leerink Partners

June 30, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

June 30, 2025 | marketbeat.com

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

June 30, 2025 | businesswire.com

Oppenheimer Asset Management Inc. Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 30, 2025 | marketbeat.com

Zai Lab (ZLAB) chief legal officer sells $212k in shares

June 29, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR, ZLAB, PTCT, FGEN, and EBS Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$18.31 -0.55 (-2.92%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$18.27 -0.04 (-0.22%)

As of 07/11/2025 07:54 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Emergent Biosolutions NYSE:EBS

$7.34 +0.01 (+0.14%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$7.28 -0.06 (-0.76%)

As of 07/11/2025 07:50 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

FibroGen NASDAQ:FGEN

$7.15 -0.20 (-2.72%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$7.30 +0.15 (+2.10%)

As of 07/11/2025 07:00 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

PTC Therapeutics NASDAQ:PTCT

$48.55 -0.97 (-1.96%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$49.34 +0.79 (+1.62%)

As of 07/11/2025 07:59 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Zai Lab NASDAQ:ZLAB

$32.73 -1.35 (-3.96%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$32.74 +0.01 (+0.02%)

As of 07/11/2025 07:58 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time